FORM 51-102F3 MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Cannvas MedTech Inc. (the "Company" or "Cannvas") 804-750 West Pender Street

Vancouver, BC V6C 2T7

Item 2: Date of Material Change

March 26, 2019.

Item 3: News Release

News releases were disseminated on March 26, 2019 and filed on SEDAR (www.sedar.com).

Item 4: Summary of Material Changes

The Company announced that it has experienced unprecedented growth of its Cannvas.Me (www.cannvas.me) digital cannabis education platform as more global users from over 80 countries and 1,100 cities turn to Cannvas.Me for credible and evidence-based cannabis education.

Additionally, the Company also announced that it has issued shares to a consultant.

Item 5: Full Description of Material Change

The Company announced that it has experienced unprecedented growth of its Cannvas.Me (www.cannvas.me) digital cannabis education platform as more global users from over 80 countries and 1,100 cities turn to Cannvas.Me for credible and evidence-based cannabis education. With user growth exceeding expectations and the platform's global reach expanding at a rapid pace, Cannvas.Me is poised to become the household name for cannabis education all while increasing its unique dataset to paint a clearer picture of cannabis consumption across Canada.

Since the launch of Cannvas.Me in October, the educational platform has experienced a consistent month-to-month user growth of 30%, with a meteoric rise of 524% in March. The site is now on track to have over 4 million unique users accessing its free and unbiased cannabis education in 2019, with over 50 million views of Cannvas articles and courses before year's end.

This puts Cannvas on track to have over 90% of countries around the world engaging with its content before the end of 2019.

The average session duration for Cannvas.Me users has also increased month-to-month since the site's launch, up 10% each month in the past six months. With users spending an average of nearly 10 minutes on the site per visit.

Additionally, the Company announced that it has issued a total of 38,000 common shares at a deemed price of \$0.265 per common share to a service provider pursuant to a consulting agreement entered into with the service provider.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

For further information, please contact:

CannvasMedTech.com

Contact: ir@cannvasmedtech.com

Item 9: Date of Report

March 26, 2019.